노보 노디스크 (NVO)

Mar 19, 2026

Novo Nordisk Secures FDA Approval For Higher-Dose Wegovy - Benzinga

Mar 19, 2026

Mar 18, 2026

Novo Nordisk A/S stock faces pressure from FDA warning on semaglutide reporting and Bernstein Underp - AD HOC NEWS

Mar 18, 2026

Mar 18, 2026

Novo Nordisk A/S stock faces headwinds from CagriSema trial setback amid buyback progress and compet - AD HOC NEWS

Mar 18, 2026

Mar 17, 2026

Novo Nordisk A/S stock rebounds on UBT251 trial data amid CEO turmoil and buyback momentum - AD HOC NEWS

Mar 17, 2026

Mar 16, 2026

Novo Nordisk A/S - GlobeNewswire Inc.

Mar 16, 2026

Mar 15, 2026

Novo Nordisk A/S Stock (ISIN: DK0062498333) Faces Headwinds from FDA Warning Amid GLP-1 Demand - AD HOC NEWS

Mar 15, 2026

Mar 15, 2026

Novo Nordisk A/S Stock Faces Brutal Choice: Can Oral Wegovy Rescue the Semaglutide Empire? - AD HOC NEWS

Mar 15, 2026

Mar 14, 2026

FDA Warning Tests Novo Nordisk Compliance And Reshapes NYSE NVO Risk Profile - Sahm

Mar 14, 2026

Mar 14, 2026

Novo Nordisk Telehealth Deal Weighs On Weak Share Price And Valuation - Sahm

Mar 14, 2026

Mar 13, 2026

NVO Stock Quote Price and Forecast - CNN

Mar 13, 2026

Mar 10, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/SNVO - ChartMill

Mar 10, 2026

Mar 10, 2026

Novo Nordisk A/S (NVO) Expands Manufacturing to Support Rising Global Demand for GLP-1 Drugs - Finviz

Mar 10, 2026

Mar 10, 2026

Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal - Finviz

Mar 10, 2026

Mar 10, 2026

Novo Nordisk 2026 Dividend Guide for UAE Investors - Bitget

Mar 10, 2026

Mar 09, 2026

Morgan Stanley Upgrades Novo Nordisk A/S (NVO) to Equal Weight From UnderweightHere's Why - Finviz

Mar 09, 2026

Mar 07, 2026

Novo Nordisk Faces Securities Probe And GLP-1 Compounding Crackdown - Sahm

Mar 07, 2026

Mar 06, 2026

Novo Nordisk (NVO) Reports 10% Sales Growth as Obesity Care Hits DKK 82B - Finviz

Mar 06, 2026

Mar 06, 2026

Roche's Obesity Drug Shows Promise But Trails GLP-1 Giants Novo Nordisk, Eli Lilly - Sahm

Mar 06, 2026

Mar 04, 2026

GLP-1 Receptor Agonist Business Analysis Report 2026: Market to Reach $137.4 Billion by 2030 - GlobeNewswire Inc.

Mar 04, 2026

Mar 04, 2026

NVO Earnings History & Surprises | EPS & Revenue Results | NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) - ChartMill

Mar 04, 2026

Mar 04, 2026

Novo Nordisk’s New Sogroya Uses And Vivtex Deal Test Valuation Gap - Sahm

Mar 04, 2026

Mar 03, 2026

JPMorgan prices Digital Barrier Notes linked to Novo Nordisk (AMJB) with 24.25% digital return - Stock Titan

Mar 03, 2026

Mar 01, 2026

Static price chart | MORGAN STANLEY PLC/CALL/NOVO NORDISK ADR B/100/0.1/18.12.26 | DE000MJ595A5 - marketscreener.com

Mar 01, 2026

Mar 01, 2026

Novo Nordisk A/S (NVO) Announces FDA Approval of Three New Indications for Sogroya - Finviz

Mar 01, 2026

Feb 28, 2026

Novo Nordisk A/S (NVO) and Vivtex Corporation Announce a Partnership - Finviz

Feb 28, 2026

Feb 27, 2026

Novo Nordisk Sales Warning Tests GLP-1 Reliance And Future Growth Story - Sahm

Feb 27, 2026

Feb 27, 2026

NVO Price History for Novo Nordisk A/S ADR Stock - Barchart.com

Feb 27, 2026

Feb 27, 2026

Novo Nordisk's Shares Drop 16.43% on CagriSema Setback and Legal Scrutiny Trading Volume Slides to 184th - Bitget

Feb 27, 2026

Feb 26, 2026

Jim Cramer Recommends Eli Lilly over Novo Nordisk - Finviz

Feb 26, 2026

Feb 25, 2026

Novo Nordisk's 40% Fall May Be Creating A Deep-Value Moment - Finviz

Feb 25, 2026

Feb 25, 2026

European ADRs Rose In US Trading, Led By HSBC And Sequans - Finimize

Feb 25, 2026

Feb 25, 2026

Ozempic Price War - Benzinga

Feb 25, 2026